Latest market price
59.88
-1.37-2.24%
ATRCQT68AtriCure, Inc.·NASDAQ
59.88-2.24%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)0.21Insider Own5.57%Shs Outstand50.87MPerf Week-1.96%
Market Cap3.05BForward P/E142.45EPS next Y0.42Insider Trans-2.92%Shs Float48.83MPerf Month8.60%
Enterprise Value2.95BPEG3.73EPS next Q-0.05Short Float10.01%Perf Quarter53.54%
Income11.00MP/S5.34EPS this Y—Short Ratio4.48Perf Half Y108.06%
Sales570.00MP/B5.90EPS next Y287.89%ROA1.56%Short Interest4.89MPerf YTD51.37%
Book/sh10.14P/C18.13EPS next 5Y76.43%ROE2.14%52W High63.00 -4.95%Perf Year75.65%
Cash/sh3.30P/FCF53.44EPS past 3/5Y—ROIC2.04%52W Low25.36 136.12%Perf 3Y76.69%
Dividend Est.—EV/EBITDA77.60Sales past 3/5Y17.48% 20.91%Gross Margin76.16%Volatility3.48% 3.74%Perf 5Y-18.64%
Dividend TTM—EV/Sales5.17EPS Y/Y TTM—Oper. Margin2.44%ATR (14)2.20Perf 10Y242.56%
Dividend Ex-Date—Quick Ratio3.19Sales Y/Y TTM14.00%Profit Margin1.85%RSI (14)57.18Recom2.10
Dividend Gr. 3/5Y—Current Ratio4.22EPS Q/Q238.46%SMA203.45%Beta1.20Target Price57.29
Payout0.00%Debt/Eq0.14Sales Q/Q13.24%SMA507.31%Rel Volume1.10Prev Close61.25
Employees1,350LT Debt/Eq0.14EarningsNov 03SMA20056.85%Avg Volume1.01MPrice59.88
IPO DateAug 05, 2005Option/ShortYes / YesEPS/Sales Surpr.10846.27% 1.19%Net Debt/EBITDA-2.55Volume1,115,758Change-2.24%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-02-26DowngradeFreedom Capital MarketsBuy → Hold
Sep-17-26ReiteratedStifel NicolausBuy$26 → $65
Sep-02-26ReiteratedNeedhamBuy$40 → $64
Aug-27-26ReiteratedPiper SandlerOverweight$40 → $60
Aug-24-26ReiteratedBTIGBuy$54 → $55
Jul-28-26ReiteratedUBSBuy$55 → $50
Jul-21-26ReiteratedRaymond James$52
May-06-26ReiteratedCanaccord GenuityBuy$53 → $55
Feb-18-26ReiteratedCanaccord GenuityBuy$64 → $53
Feb-18-26ReiteratedUBSBuy$55
Latest News· Times ET
Oct-28-26
Oct-26-26
Oct-21-26
Oct-14-26
Oct-13-26
Oct-12-26
Oct-04-26
Oct-02-26
Sep-25-26
Sep-21-26
Sep-15-26
Sep-14-26
Sep-12-26
Sep-12-2607:45PM
Sep-10-26
Company

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue570535465399—————
Cost of Goods Sold Incl. D&A13613711899—————
Gross Profit434398348300—————
Selling, General and Administrative Excl. Other324311291253—————
Research and Development96909674—————
Other Operating Expense0010—————
Operating Income14-3-40-27—————
Interest Expense7667—————
Unusual Expense
—————————
Non-Operating Income (Expense)5-134—————
Net Income Before Taxes11-10-44-30—————
Income Taxes1111—————
Consolidated Net Income11-11-45-30—————
Net Income From Continuing Operations11-11-45-30—————
Net Income11-11-45-30—————
EPS (Recurring)0.21-0.24-0.95-0.66—————
EPS (Basic, Before Extraordinaries)0.21-0.24-0.95-0.66—————
EPS (Diluted)0.21-0.24-0.95-0.66—————
EBITDA3816-19-8—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
285.14————————
Price To Sales Ratio5.153.553.094.11—————
Gross Margin76.1474.3974.8475.19—————
Operating Margin2.46-0.56-8.60-6.77—————
Net Margin1.93-2.06-9.68-7.52—————
Shares Outstanding49484746—————
Market Capitalization2,9341,8991,4361,642—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$67.97$56.07$44.17$32.27$20.37● Close Price0.00M0.35M0.71M1.06M1.42MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Privitera SalvatoreChief Technical OfficerSep 23 '26Sale60.004,519271,140142,745Sep 24
GROVES REGINA EDirectorSep 11 '26Sale54.225,313288,07134,546Sep 14
Privitera SalvatoreChief Technical OfficerSep 08 '26Sale55.003,657201,135147,264Sep 10
Privitera SalvatoreChief Technical OfficerSep 02 '26Sale52.507,763407,558150,921Sep 04
Dahlquist Karl S.Chief Legal OfficerAug 24 '26Sale48.899,370458,09987,319Aug 26
Yuen MaggieDirectorAug 05 '26Sale38.423,500134,47014,015Aug 07
Prange KarenDirectorAug 05 '26Sale38.803,564138,28322,809Aug 07
Noznesky Justin JChief Mktg & Strategy OfficerJul 29 '26Sale38.806,182239,862100,219Jul 30
Doraiswamy VinayakChief Scientific OfficerJul 28 '26Sale38.886,000233,28086,511Jul 30
WEHRWEIN SVENDirectorJul 28 '26Option Exercise19.9525,000498,75065,518Jul 30
WEHRWEIN SVENDirectorJul 28 '26Sale37.8425,000946,00040,518Jul 30
Prange KarenDirectorMay 20 '26Sale28.653,00085,95026,373May 22
Doraiswamy VinayakChief Scientific OfficerMay 15 '26Sale28.135,000140,65091,875May 18
Doraiswamy VinayakChief Scientific OfficerMar 12 '26Sale29.835,000149,15096,875Mar 16
WHITE ROBERT S.DirectorMar 10 '26Option Exercise14.9910,000149,900122,174Mar 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.